Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianlin Xu

Showing results (21-30 of 135) with videos related to

Pageof 14
Sort By:
Lung Cancer (Amsterdam, Netherlands)|September 19, 2020
Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencingJingwen Li, Yue Wang, Bo Zhang, et al.
Annals of Palliative Medicine|March 12, 2020
Radiofrequency ablation of synchronous multiple primary lung cancer assisted by a magnetic navigation system: a case reportJiajun Teng, Jianlin Xu, Jing Jiao, et al.
Cancer Medicine|October 17, 2022
Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancerLian Yu, Jianlin Xu, Rong Qiao, et al.
Current Computer-Aided Drug Design|March 13, 2026
Mechanistic Study of Traditional Chinese Medicine Compound Containing Ginseng Radix et Rhizoma in the Treatment of Colorectal CancerWei Yue, Liwen Zhang, Jiazhi Xu, et al.
Frontiers in Oncology|September 13, 2021
Patterns of Recurrence and Survival Rate After Complete Resection of Pathological Stage N2 Small-Cell Lung CancerLian Yu, Jianlin Xu, Rong Qiao, et al.
Translational Oncology|April 17, 2023
Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progressionYingqi Xu, Jianlin Xu, Rong Qiao, et al.
Lung Cancer (Amsterdam, Netherlands)|July 17, 2024
Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLCYingqi Xu, Yidan Zhang, Huiping Qiang, et al.
Sensors (Basel, Switzerland)|June 12, 2026
Nonlinearity-Guided Dual-Spectrum Ultrasonic Inversion for Attenuation-Independent Characterization of Subwavelength CoatingsLei Wang, Cong Wan, Jiacheng Wang, et al.
Biotechnology and Bioengineering|September 11, 2023
Recent advances in upstream process development for production of recombinant adeno-associated virusJianfa Ou, Yawen Tang, Jianlin Xu, et al.
Translational Lung Cancer Research|June 16, 2023
Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort studyLian Yu, Jianlin Xu, Rong Qiao, et al.
Pageof 14

Showing results (21-30 of 135) with videos related to

Sort By:
Pageof 14
Lung Cancer (Amsterdam, Netherlands)|September 19, 2020
Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencingJingwen Li, Yue Wang, Bo Zhang, et al.
Annals of Palliative Medicine|March 12, 2020
Radiofrequency ablation of synchronous multiple primary lung cancer assisted by a magnetic navigation system: a case reportJiajun Teng, Jianlin Xu, Jing Jiao, et al.
Cancer Medicine|October 17, 2022
Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancerLian Yu, Jianlin Xu, Rong Qiao, et al.
Current Computer-Aided Drug Design|March 13, 2026
Mechanistic Study of Traditional Chinese Medicine Compound Containing Ginseng Radix et Rhizoma in the Treatment of Colorectal CancerWei Yue, Liwen Zhang, Jiazhi Xu, et al.
Frontiers in Oncology|September 13, 2021
Patterns of Recurrence and Survival Rate After Complete Resection of Pathological Stage N2 Small-Cell Lung CancerLian Yu, Jianlin Xu, Rong Qiao, et al.
Translational Oncology|April 17, 2023
Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progressionYingqi Xu, Jianlin Xu, Rong Qiao, et al.
Lung Cancer (Amsterdam, Netherlands)|July 17, 2024
Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLCYingqi Xu, Yidan Zhang, Huiping Qiang, et al.
Sensors (Basel, Switzerland)|June 12, 2026
Nonlinearity-Guided Dual-Spectrum Ultrasonic Inversion for Attenuation-Independent Characterization of Subwavelength CoatingsLei Wang, Cong Wan, Jiacheng Wang, et al.
Biotechnology and Bioengineering|September 11, 2023
Recent advances in upstream process development for production of recombinant adeno-associated virusJianfa Ou, Yawen Tang, Jianlin Xu, et al.
Translational Lung Cancer Research|June 16, 2023
Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort studyLian Yu, Jianlin Xu, Rong Qiao, et al.
Pageof 14